Ricky Chiu, CEO, Phase Scientific Intl, Hong Kong
08.10.2018
Related Interviews
Alex Zhavoronkov – CEO, Insilico Medicine
Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative…
Albert Yu – Chairman, Hong Kong Biotechnology Organization (HKBIO)
Dr Albert Yu, chairman of the Hong Kong Biotechnology Organization (HKBIO) gives his expert insights into the crucial importance of diagnostics in countering the COVID-19 pandemic, how Hong Kong’s positioning…
Alex Wong – CEO, Xcelom
Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong…
Hong Kong / HKEX Continues Biotech Momentum in Q3 2021
Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings.…
China / Sinopharm Looks to mRNA Vaccines; Hong Kong Biotech Investment Continues to Boom; Another Big Manufacturing Investment for Lonza
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its own mRNA vaccine; an update on Hong Kong’s biotech investment ecosystem three year…
Hong Kong / HKEX Biotech IPOs in the First Half of 2021
Three years after the Hong Kong Stock Exchange (HKEX) introduced reforms to allow and support the listing of pre-profit biotech companies, it has become Asia’s largest, and the world’s second-largest,…
Latest Report
